Format

Send to

Choose Destination
Gynecol Oncol. 2000 Mar;76(3):336-9.

Serum MAGE-4 protein in ovarian cancer patients.

Author information

1
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, 830, Japan.

Abstract

OBJECTIVE:

We measured serum levels of MAGE-4 protein in patients with ovarian cancer to investigate the relationship between serum MAGE-4 positivity and prognosis.

METHODS:

Serum levels of MAGE-4 protein were measured with an ELISA system.

RESULTS:

Serum levels of MAGE-4 in patients with ovarian cancer were significantly higher than levels in patients with benign diseases. Serum MAGE-4 protein was considered positive in 22% of primary ovarian cancer patients. The positive rate was the highest in sera of patients with surface epithelial-stromal tumors, particularly serous adenocarcinomas (24%). The survival time after a primary surgical operation in ovarian cancer patients with serum MAGE-4 positivity was significantly shorter than that of MAGE-4-negative cases.

CONCLUSION:

These results suggest that serum MAGE-4 protein is a potential prognostic factor of reduced survival in ovarian cancer patients.

PMID:
10684707
DOI:
10.1006/gyno.1999.5701
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center